TSHA Quote, Financials, Valuation and Earnings

Aspire Biopharma Holdings, Inc. has a net margin of -1353.58% compared to Taysha Gene Therapies, Inc.'s net margin of -97394.74%. Taysha Gene Therapies, Inc.'s return on equity of -73.14% beat Aspire Biopharma Holdings, Inc.'s return on equity of --.

Taysha Gene Therapies, Inc. has a consensus price target of $10.79, signalling upside risk potential of 85%. On the other hand Aspire Biopharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Taysha Gene Therapies, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe Taysha Gene Therapies, Inc. is more attractive than Aspire Biopharma Holdings, Inc..

Taysha Gene Therapies, Inc. has a beta of 1.056, which suggesting that the stock is 5.563% more volatile than S&P 500. In comparison Aspire Biopharma Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Taysha Gene Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aspire Biopharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Taysha Gene Therapies, Inc. pays -- of its earnings as a dividend. Aspire Biopharma Holdings, Inc. pays out -- of its earnings as a dividend.

Taysha Gene Therapies, Inc. quarterly revenues are --, which are smaller than Aspire Biopharma Holdings, Inc. quarterly revenues of $1.9K. Taysha Gene Therapies, Inc.'s net income of -$32.7M is lower than Aspire Biopharma Holdings, Inc.'s net income of -$1.9M. Notably, Taysha Gene Therapies, Inc.'s price-to-earnings ratio is -- while Aspire Biopharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Taysha Gene Therapies, Inc. is 259.98x versus 2,053.63x for Aspire Biopharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Anavex Life Sciences Corp. has a net margin of -1353.58% compared to Taysha Gene Therapies, Inc.'s net margin of --. Taysha Gene Therapies, Inc.'s return on equity of -73.14% beat Anavex Life Sciences Corp.'s return on equity of -44.87%.

Taysha Gene Therapies, Inc. has a consensus price target of $10.79, signalling upside risk potential of 85%. On the other hand Anavex Life Sciences Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 504.4%. Given that Anavex Life Sciences Corp. has higher upside potential than Taysha Gene Therapies, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Taysha Gene Therapies, Inc..

Taysha Gene Therapies, Inc. has a beta of 1.056, which suggesting that the stock is 5.563% more volatile than S&P 500. In comparison Anavex Life Sciences Corp. has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.531%.

Taysha Gene Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Taysha Gene Therapies, Inc. pays -- of its earnings as a dividend. Anavex Life Sciences Corp. pays out -- of its earnings as a dividend.

Taysha Gene Therapies, Inc. quarterly revenues are --, which are smaller than Anavex Life Sciences Corp. quarterly revenues of --. Taysha Gene Therapies, Inc.'s net income of -$32.7M is lower than Anavex Life Sciences Corp.'s net income of -$9.8M. Notably, Taysha Gene Therapies, Inc.'s price-to-earnings ratio is -- while Anavex Life Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Taysha Gene Therapies, Inc. is 259.98x versus -- for Anavex Life Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Bolt Biotherapeutics, Inc. has a net margin of -1353.58% compared to Taysha Gene Therapies, Inc.'s net margin of -329.37%. Taysha Gene Therapies, Inc.'s return on equity of -73.14% beat Bolt Biotherapeutics, Inc.'s return on equity of -86.41%.

Taysha Gene Therapies, Inc. has a consensus price target of $10.79, signalling upside risk potential of 85%. On the other hand Bolt Biotherapeutics, Inc. has an analysts' consensus of $22.00 which suggests that it could grow by 312.76%. Given that Bolt Biotherapeutics, Inc. has higher upside potential than Taysha Gene Therapies, Inc., analysts believe Bolt Biotherapeutics, Inc. is more attractive than Taysha Gene Therapies, Inc..

Taysha Gene Therapies, Inc. has a beta of 1.056, which suggesting that the stock is 5.563% more volatile than S&P 500. In comparison Bolt Biotherapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Taysha Gene Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bolt Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Taysha Gene Therapies, Inc. pays -- of its earnings as a dividend. Bolt Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Taysha Gene Therapies, Inc. quarterly revenues are --, which are smaller than Bolt Biotherapeutics, Inc. quarterly revenues of $2.2M. Taysha Gene Therapies, Inc.'s net income of -$32.7M is lower than Bolt Biotherapeutics, Inc.'s net income of -$7.1M. Notably, Taysha Gene Therapies, Inc.'s price-to-earnings ratio is -- while Bolt Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Taysha Gene Therapies, Inc. is 259.98x versus 11.31x for Bolt Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neurogene, Inc. has a net margin of -1353.58% compared to Taysha Gene Therapies, Inc.'s net margin of -1999.14%. Taysha Gene Therapies, Inc.'s return on equity of -73.14% beat Neurogene, Inc.'s return on equity of -33.3%.

Taysha Gene Therapies, Inc. has a consensus price target of $10.79, signalling upside risk potential of 85%. On the other hand Neurogene, Inc. has an analysts' consensus of $59.00 which suggests that it could grow by 194.85%. Given that Neurogene, Inc. has higher upside potential than Taysha Gene Therapies, Inc., analysts believe Neurogene, Inc. is more attractive than Taysha Gene Therapies, Inc..

Taysha Gene Therapies, Inc. has a beta of 1.056, which suggesting that the stock is 5.563% more volatile than S&P 500. In comparison Neurogene, Inc. has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.381%.

Taysha Gene Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurogene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Taysha Gene Therapies, Inc. pays -- of its earnings as a dividend. Neurogene, Inc. pays out -- of its earnings as a dividend.

Taysha Gene Therapies, Inc. quarterly revenues are --, which are smaller than Neurogene, Inc. quarterly revenues of --. Taysha Gene Therapies, Inc.'s net income of -$32.7M is lower than Neurogene, Inc.'s net income of -$21M. Notably, Taysha Gene Therapies, Inc.'s price-to-earnings ratio is -- while Neurogene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Taysha Gene Therapies, Inc. is 259.98x versus -- for Neurogene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.